Targets

What are companies targeting with each different modality?

What are the targets of the therapeutics you are working on?

When asked about what respondents are targeting with antibody therapeutics, unsurprisingly cancer comes out top by far with 73% of respondents. Auto-immune (36%) and infectious (27%) diseases are the next most common targets.

What are the targets of the therapeutics you are working on? - BY MODALITY

When comparing targets by different modalities, some interesting differences emerge. For example there is over 20% difference between modalities for cancer, auto-immune diseases, rare diseases and infectious diseases.

On the following pages we take a closer look at some of these.

What are the targets of the protein therapeutics you are working on?

A higher proportion of respondents working on protein therapeutics target auto-immune diseases (48%), diabetes/ obesity (16%), rare diseases (31%) and haematological diseases (25%) than any other modality, showing their versatility.

Other responses included 'antivenom' and 'fibrotic diseases'.

Which therapeutic(s) are you using to treat infectious diseases?

Infectious diseases are the third most common target for respondents, but the use between different modalities varies hugely. Protein therapeutics (42%) and mAbs (43%) lead the way, whilst none of the others garnered even half as many responses.